Search Results

You are looking at 1 - 10 of 214 items for :

Clear All
Full access

Yixing Jiang, Heath Mackley, Hua Cheng and Jaffer A. Ajani

. However, the procedure requires a permanent colostomy. In 1983, Nigro et al. 6 showed that a complete pathologic response could be achieved with the combination of mitomycin C (MMC), 5-fluorouracil (5-FU), and 30 Gy of pelvic radiotherapy before

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt and Benjamin R. Tan

-FU) based on patient and physician discretion and 41 (60.3%) received gemcitabine in combination with a platinum drug (cisplatin or oxaliplatin). A total of 7 patients were treated with sorafenib, 3 were treated with 5-FU alone, and 1 was treated with

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins and Michael J. Sorich

-FU with leucovorin and irinotecan (folinic acid/5-FU/irinotecan [FOLFIRI] or irinotecan/5-FU/leucovorin [IFL]) was the chemotherapy in all trials except N016966 and HORIZON III, in which a fluoropyrimidine was combined with oxaliplatin. Among the

Full access

Cintia Yoko Morioka, Marcel Cerqueira Cesar Machado, Jose Pinhata Otoch, Luma Princess Schneider, Edgard Mesquita Rodrigues Lima, Marcelo Engracia Garcia, Joelmir Silva, Alessandro Costa, Victor Herrera, Paulo Aguiar, Elenir Herrera, Talita Aguiar, Maycon Kublik, Amelia Silva, Kennedy Silva, Eduardo Morioka and Ching Cheng Huang

were used for the experiments. 5-Fluorouracil (5FU), Gemcitabine (GEM) and green tea extract (GTE) were used. MTT assay and MTT agarose assay were performed. In vitro chemoinvasion assay was done. RESULTS: The inhibitory concentration (IC50) of 5-FU

Full access

Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister and Hermann Brenner

recommended for patients with stage III colon cancer, beginning in the 1990s. In 2004, results from the MOSAIC trial showed that a combination of oxaliplatin with conventional 5-FU/leucovorin (LV) chemotherapy significantly improved 3-year disease

Full access

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Alan P. Venook

otherwise experience a cure—did not turn out to be the case,” Dr. Venook stated. Figure 1. Colorectal cancer: 20 years later. Abbreviations: 5-FU, 5-fluorouracill; LV, leucovorin. Another lesson learned has been regarding inconsistent

Full access

Angela Jain, Paula D. Ryan and Michael V. Seiden

discomfort, and a CT scan showed extensive metastatic disease to the liver and retroperitoneal and para-aortic lymphadenopathy. Biopsy of a liver metastasis confirmed metastatic mucinous cystadenocarcinoma. The patient received 5-FU, leucovorin, and

Full access

Katherine Van Loon and Alan P. Venook

Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research

Full access

Ludmila Katherine Martin and Tanios Bekaii-Saab

. Neoadjuvant Chemoradiation Using 5-FU Neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) represents a standard treatment approach for patients with T3-4 and/or node-positive rectal cancer (stage II-III disease). Despite the lack of a survival benefit